Given the highly multifactorial origin of Alzheimer’s disease (AD) neuropathology, disentangling and orderly knowing mechanisms involved in sporadic onset are arduous. Nevertheless, when the elements involved are dissected into smaller pieces, the task becomes more accessible. This review aimed to describe the link between c-Jun N-terminal Kinases (JNKs), master regulators of many cellular functions, and the early alterations of AD: synaptic loss and dysregulation of neuronal transport. Both processes have a role in the posterior cognitive decline observed in AD. The manuscript focuses on the molecular mechanisms of glutamatergic, GABA, and cholinergic synapses altered by the presence of amyloid-β aggregates and hyperphosphorylated tau, as well as on several consequences of the disruption of cellular processes linked to neuronal transport that is controlled by the JNK-JIP (c-jun NH2-terminal kinase (JNK)–interacting proteins (JIPs) complex, including the transport of AβPP or autophagosomes.
WellerJ, BudsonA (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res7, F1000 Faculty Rev-1161.
3.
AlzheimerA (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych Med64, 146–148.
4.
KarranE, MerckenM, Strooper DeB (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov10, 698–712.
5.
ZhuX, PerryG, MoreiraPI, AlievG, CashAD, HiraiK, SmithMA (2006) Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis9, 147–153.
NewcombeEA, Camats-PernaJ, SilvaML, ValmasN, HuatTJ, MedeirosR (2018) Inflammation: The link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation15, 1–26.
10.
BostancıklıogluM (2019) An update on the interactions between Alzheimer’s disease, autophagy and inflammation. Gene705, 157–166.
11.
SwerdlowRH (2018) Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis62, 1403–1416.
12.
AlbensiBC (2019) Dysfunction of mitochondria: Implications for Alzheimer’s disease. Int Rev Neurobiol145, 13–27.
ZhangY, ChenX, ZhaoY, PonnusamyM, LiuY (2017) The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer’s disease. Rev Neurosci28, 861–868.
15.
SteenE, TerryBM, RiveraJE, CannonJL, NeelyTR, TavaresR, XuXJ, WandsJR, de la MonteSM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease –is this type 3 diabetes? J Alzheimers Dis7, 63–80.
16.
EttchetoM, CanoA, BusquetsO, ManzinePR, Sanchez-LópezE, Castro-TorresRD, Beas-ZarateC, VerdaguerE, GarcíaML, OlloquequiJ, AuladellC, FolchJ, CaminsA (2019) A metabolic perspective of late onset Alzheimer’s disease. Pharmacol Res145, 104255.
17.
FolchJ, OlloquequiJ, EttchetoM, BusquetsO, Sanchez-LópezE, CanoA, Espinosa-JimenezT, GarcíaML, Beas-ZarateC, CasadesúsG, BullóM, AuladellC, CaminsA (2019) The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front Aging Neurosci11, 1–16.
18.
EttchetoM, BusquetsO, Espinosa-JimenezT, VerdaguerE, AuladellC, CaminsA (2020) A chronological review of potential disease-modifying therapeutic strategies for Alzheimer’s disease. Curr Pharm Des26, 1286–1299.
19.
Vicario-OrriE, OpazoCM, MuñozFJ (2015) The pathophysiology of axonal transport in Alzheimer’s disease. J Alzheimers Dis43, 1097–1113.
20.
WangZX, TanL, YuJT (2015) Axonal transport defects in Alzheimer’s disease. Mol Neurobiol51, 1309–1321.
21.
KamatP, KalaniA, RaiS, SwarnkarS, TotaS, NathC, TyagiN (2016) Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer’s disease: Understanding the therapeutics strategies. Mol Neurobiol53, 648–661.
22.
CombsB, MuellerRL, MorfiniG, BradyST, KanaanNM (2019) Tau and axonal transport misregulation in tauopathies. Adv Exp Med Biol1184, 81–95.
23.
SabapathyK (2012) Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci106, 145–169.
AntoniouX, BorselloT (2012) The JNK signalling transduction pathway in the brain. Front Biosci (Elite Ed)4, 2110–2120.
26.
CoffeyET (2014) Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci15, 285–299.
27.
GreenDR, LlambiF (2015) Cell death signaling. Cold Spring Harb Perspect Biol7, 1–24.
28.
YarzaR, VelaS, SolasM, RamirezMJ (2016) c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease. Front Pharmacol6, 321.
29.
GourmaudS, PaquetC, DumurgierJ, PaceC, BourasC, GrayF, LaplancheJL, MeursEF, Mouton-LigerF, HugonJ (2015) Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: Links to cognitive decline. J Psychiatry Neurosci40, 151–161.
30.
MorishimaY, GotohY, ZiegJ, BarrettT, TakanoH, FlavellR, DavisRJ, ShirasakiY, GreenbergME (2001)
β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of fas ligand. J Neurosci21, 7551–7560.
31.
SavageMJ, LinYG, CiallellaJR, FloodDG, ScottRW (2002) Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J Neurosci22, 3376–3385.
32.
ColomboA, BastoneA, PloiaC, SclipA, SalmonaM, ForloniG, BorselloT (2009) JNK regulates APP cleavage and degradation in a model of Alzheimer’s disease. Neurobiol Dis33, 518–525.
33.
LagalwarS, Guillozet-BongaartsAL, BerryRW, BinderLI (2006) Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease. J Neuropathol Exp Neurol65, 455–464.
GiulianiD, OttaniA, ZaffeD, GalantucciM, StrinatiF, LodiR, GuariniS (2013) Hydrogen sulfide slows down progression of experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms. Neurobiol Learn Mem104, 82–91.
36.
SolasM, AisaB, TorderaRM, MuguetaMC, RamírezMJ (2013) Stress contributes to the development of central insulin resistance during aging: Implications for Alzheimer’s disease. Biochim Biophys Acta1832, 2332–2339.
37.
MarquesCA, KeilU, BonertA, SteinerB, HaassC, MüllerWE, EckertA (2003) Neurotoxic mechanisms caused by the Alzheimer’s disease-linked Swedish amyloid precursor protein. Mutation oxidative stress, caspases, and the JNK pathway. J Biol Chem278, 28294–28302.
38.
SaharaN, MurayamaM, LeeB, ParkJM, LagalwarS, BinderLI, TakashimaA (2008) Active c-jun N-terminal kinase induces caspase cleavage of Tau and additional phosphorylation by GSK-3β is required for tau aggregation. Eur J Neurosci27, 2897–2906.
39.
CondeC, CaceresA (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci10, 319–332.
40.
HotulainenP, HoogenraadCC (2010) Actin in dendritic spines: Connecting dynamics to function. J Cell Biol189, 619–629.
41.
MehanS, MeenaH, SharmaD, SankhlaR (2011) JNK: A stress-activated protein kinase therapeutic strategies and involvement in Alzheimer’s and various neurodegenerative abnormalities. J Mol Neurosci43, 376–390.
42.
BriggsCA, ChakrobortyS, StutzmannGE (2017) Emerging pathways driving early synaptic pathology in Alzheimer’s disease. Biochem Biophys Res Commun483, 988–997.
CefalielloC, PennaE, BarbatoC, Di RubertoG, MollicaMP, TrincheseG, CiglianoL, BorselloT, ChunJT, GiudittaA, Perrone-CapanoC, MiniaciMC, CrispinoM (2020) Deregulated local protein synthesis in the brain synaptosomes of a mouse model for Alzheimer’s disease. Mol Neurobiol57, 1529–1541.
47.
OverkCR, MasliahE (2014) Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharmacol88, 508–516.
48.
SclipA, TozziA, AbazaA, CardinettiD, ColomboI, CalabresiP, SalmonaM, WelkerE, BorselloT (2014) c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis5, e1019.
49.
BordjiK, Becerril-OrtegaJ, BuissonA (2011) Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s disease. Rev Neurosci22, 285–294.
50.
AmatniekJC, HauserWA, DelCastillo-CastanedaC, JacobsDM, MarderK, BellK, AlbertM, BrandtJ, SternY (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia47, 867–872.
51.
AuladellC, De LemosL, VerdaguerE, EttchetoM, BusquetsO, LazarowskiA, Beas-ZarateC, OlloquequiJ, FolchJ, CaminsA (2017) Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Front Biosci (Landmark Ed)22, 795–814.
52.
BusquetsO, EttchetoM, CanoA, R. ManzineP, Sanchez-LopezE, Espinosa-JimenezT, VerdaguerE, DarioCastro-TorresR, Beas-ZarateC, X. SuredaF, OlloquequiJ, AuladellC, FolchJ, CaminsA (2019) Role of c-Jun N-Terminal Kinases (JNKs) in epilepsy and metabolic cognitive impairment. Int J Mol Sci21, 255.
53.
TaiTY, WarnerLN, JonesTD, JungS, ConcepcionFA, SkyrudDW, FenderJ, LiuY, WilliamsAD, NeumaierJF, D’AmbrosioR, PoolosNP (2017) Antiepileptic action of c-Jun N-terminal kinase (JNK) inhibition in an animal model of temporal lobe epilepsy. Neuroscience349, 35–47.
54.
ScimemiA, MeabonJS, WoltjerRL, SullivanJM, DiamondJS, CookDG (2013) Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. Ann Intern Med158, 5312–5318.
55.
ZoltowskaKM, MaesakoM, MeierJ, BerezovskaO (2018) Novel interaction between Alzheimer’s disease-related protein presenilin 1 and glutamate transporter 1. Sci Rep8, 8718.
HettingerJC, LeeH, BuG, HoltzmanDM, CirritoJR (2018) AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model. Mol Neurodegener13, 22.
58.
ZhangJ, YinY, JiZ, CaiZ, ZhaoB, LiJ, TanM, GuoG (2017) Endophilin2 interacts with GluA1 to mediate AMPA receptor endocytosis induced by oligomeric amyloid-β. Neural Plast2017, 8197085.
59.
BissenD, FossF, Acker-PalmerA (2019) AMPA receptors and their minions: Auxiliary proteins in AMPA receptor trafficking. Cell Mol Life Sci76, 2133–2169.
60.
DieringGH, HuganirRL (2018) The AMPA receptor code of synaptic plasticity. Neuron100, 314–329.
61.
LiGQ, CongDW, SunP, MengX (2018) Aβ1-42 regulates astrocytes through JNK/AP-1 pathway. Eur Rev Med Pharmacol Sci22, 2015–2021.
62.
ThomasGM, LinDT, NuriyaM, HuganirRL (2008) Rapid and bi-directional regulation of AMPA receptor phosphorylation and trafficking by JNK. EMBO J27, 361–372.
BiggiS, BuccarelloL, SclipA, LippielloP, TonnaN, RumioC, Di MarinoD, MiniaciMC, BorselloT (2017) Evidence of presynaptic localization and function of the c-Jun N-Terminal Kinase. Neural Plast2017, 6468356.
HollosP, JohnJM, LehtonenJV, CoffeyET (2020) Optogenetic control of spine-head JNK reveals a role in dendritic spine regression. eNeuro7, ENEURO.0303-19.2019.
69.
HuangSH, DuanS, SunT, WangJ, ZhaoL, GengZ, YanJ, SunHJ, ChenZY (2011) JIP3 mediates TrkB axonal anterograde transport and enhances BDNF signaling by directly bridging TrkB with kinesin-1. J Neurosci31, 10602–10614.
70.
SunT, LiY, LiT, MaH, GuoY, JiangX, HouM, HuangS, ChenZ (2017) JIP1 and JIP3 cooperate to mediate TrkB anterograde axonal transport by activating kinesin-1. Cell Mol Life Sci74, 4027–4044.
71.
ColacurcioDJ, PensalfiniA, JiangY, NixonRA (2018) Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer’s Disease. Free Radic Biol Med114, 40–51.
FahnestockM, ShekariA (2019) ProNGF and neurodegeneration in Alzheimer’s disease. Front Neurosci13, 129.
75.
SaadipourK, Mañucat-TanNB, LimY, KeatingDJ, SmithKS, ZhongJ, LiaoH, BobrovskayaL, WangY-J, ChaoMV, ZhouX-F (2018) p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis. J Neurochem144, 302–317.
76.
PalopJJ, MuckeL (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci17, 777–792.
77.
Nava-MesaMO, Jimenez-DíazL, YajeyaJ, Navarro-LopezJD (2014) GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer’s disease. Front Cell Neurosci8, 167.
GovindpaniK, Calvo-Flores GuzmánB, VinnakotaC, WaldvogelHJ, FaullRL, KwakowskyA (2017) Towards a better understanding of GABAergic remodeling in Alzheimer’s disease. Int J Mol Sci18, 1813.
80.
SelkoeDJ (2019) Early network dysfunction in Alzheimer’s disease. Science365, 540–541.
81.
RubioSE, Vega-FloresG, MartínezA, BoschC, Perez-MediavillaA, RíodelJ, GruartA, Delgado-GarcíaJM, SorianoE, PascualM (2012) Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer’s disease. FASEB J26, 4458–4467.
82.
SolerH, Dorca-ArevaloJ, GonzalezM, RubioSE, ÁvilaJ, SorianoE, PascualM (2017) The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy. Neurobiol Aging49, 40–51.
83.
Saiz-SanchezD, Ubeda-BañonI, De la Rosa-PrietoC, Martinez-MarcosA (2012) Differential expression of interneuron populations and correlation with amyloid-β deposition in the olfactory cortex of an AβPP/PS1 transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis31, 113–129.
84.
XuY, ZhaoM, HanY, ZhangH (2020) GABAergic inhibitory interneuron deficits in Alzheimer’s disease: Implications for treatment. Front Neurosci14, 660.
85.
XuJ, LiC, YinXH, ZhangGY (2008) Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology54, 1029–1040.
WuJX, ShanFX, ZhengJN, PeiDS (2014) β-arrestin promotes c-Jun N-terminal kinase mediated apoptosis via a GABABR·β-arrestin·JNK signaling module. Asian Pacific J Cancer Prev15, 1041–1046.
88.
HallDJ, HaderSN, KondilesBR (2019) The gamma-aminobutyric acid (GABA)A receptor modulates the cytokine response to rhinovirus exposure in human monocytic cells. FASEB J33, 792.4–792.4.
89.
IttnerA, IttnerLM (2018) Dendritic tau in Alzheimer’s disease. Neuron99, 13–27.
90.
IttnerLM, KeYD, DelerueF, BiM, GladbachA, van EerselJ, WölfingH, ChiengBC, ChristieMJ, NapierIA, EckertA, StaufenbielM, HardemanE, GötzJ (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell142, 387–397.
91.
HooverBR, ReedMN, SuJ, PenrodRD, KotilinekLA, GrantMK, PitstickR, CarlsonGA, LanierLM, YuanL-L, AsheKH, LiaoD (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron68, 1067–1081.
92.
Crespo-BielN, TheunisC, Van LeuvenF (2012) Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer’s disease. Int J Alzheimers Dis2012, 251426.
HeB, ChenW, ZengJ, TongW, ZhengP (2020) MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer’s disease. J Cell Physiol235, 480–493.
95.
AndreyevaA, NiewegK, HorstmannK, KlapperS, Müller-SchiffmannA, KorthC, GottmannK (2012) C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-β. Brain135, 2140–2154.
96.
Asada-UtsugiM, UemuraK, NodaY, KuzuyaA, MaesakoM, AndoK, KubotaM, WatanabeK, TakahashiM, KiharaT, ShimohamaS, TakahashiR, BerezovskaO, KinoshitaA (2011) N-cadherin enhances APP dimerization at the extracellular domain and modulates Aβ production. J Neurochem119, 354–363.
97.
GnanapavanS, GiovannoniG (2013) Neural cell adhesion molecules in brain plasticity and disease. Mult Scler Relat Disord2, 13–20.
GallowayDA, PhillipsAEM, OwenDRJ, MooreCS (2019) Phagocytosis in the brain, Homeostasis and disease. Front Immunol10, 790.
107.
WeinhardL, Di BartolomeiG, BolascoG, MachadoP, SchieberNL, NeniskyteU, ExigaM, VadisiuteA, RaggioliA, SchertelA, SchwabY, GrossCT (2018) Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction. Nat Commun9, 1–14.
108.
Colom-CadenaM, Spires-JonesT, ZetterbergH, BlennowK, CaggianoA, DekoskyST, FillitH, HarrisonJE, SchneiderLS, ScheltensP, De HaanW, GrundmanM, Van DyckCH, IzzoNJ, CatalanoSM (2020) The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alzheimers Res Ther12, 1–12.
109.
JacksonJ, JambrinaE, LiJ, MarstonH, MenziesF, PhillipsK, GilmourG (2019) Targeting the synapse in Alzheimer’s disease. Front Neurosci13, 735.
110.
ItoM, YoshiokaK, AkechiM, YamashitaS, TakamatsuN, SugiyamaK, HibiM, NakabeppuY, ShibaT, YamamotoK-I (1999) JSAP1, a novel Jun N-terminal protein kinase (JNK)-binding protein that functions as a scaffold factor in the JNK signaling pathway. Mol Cell Biol19, 7539$#x2013;7548.
111.
WilloughbyEA, PerkinsGR, CollinsMK, WhitmarshAJ (2003) The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK. J Biol Chem278, 10731–10736.
112.
KoonYL, KohCG, ChiamKH (2014) Computational modeling reveals optimal strategy for kinase transport by microtubules to nerve terminals. PLoS One9, e92437.
113.
KholodenkoBN (2002) MAP kinase cascade signaling and endocytic trafficking: A marriage of convenience? . Trends Cell Biol12, 173–177.
114.
VerheyKJ, MeyerD, DeehanR, BlenisJ, SchnappBJ, RapoportTA, MargolisB (2001) Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol152, 959–970.
115.
Dajas-BailadorF, JonesEV, WhitmarshAJ (2008) The JIP1 scaffold protein regulates axonal development in cortical neurons. Curr Biol18, 221–226.
116.
ChangKA, KimHS, HaTY, HaJW, ShinKY, JeongYH, LeeJP, ParkCH, KimS, BaikTK, SuhYH (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol26, 4327–4338.
117.
MuresanZ, MuresanV (2005) c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. J Neurosci25, 3741–3751.
118.
MengT, LinS, ZhuangH, HuangH, HeZ, HuY, GongQ, FengD (2019) Recent progress in the role of autophagy in neurological diseases. Cell Stress3, 141–161.
119.
FuMM, HolzbaurELF (2013) JIP1 regulates the directionality of APP axonal transport by coordinating kinesin and dynein motors. J Cell Biol202, 495–508.
120.
Fu mengM, HolzbaurELF (2014) Integrated regulation of motor-driven organelle transport by scaffolding proteins. Trends Cell Biol24, 564–574.
121.
EdwardsSL, YuS, HooverCM, PhillipsBC, RichmondJE, MillerKG (2013) An organelle gatekeeper function for Caenorhabditis elegans UNC-16 (JIP3) at the axon initial segment. Genetics194, 143–161.
122.
DrerupCM, NechiporukAV (2013) JNK-interacting protein 3 mediates the retrograde transport of activated c-Jun N-terminal kinase and lysosomes. PLoS Genet9, e1003303.
123.
HoeH-S, LeeH-K, PakDTS (2012) The upside of APP at synapses. CNS Neurosci Ther18, 47–56.
124.
LaßekM, WeingartenJ, WegnerM, MuellerBF, RohmerM, BaeumlisbergerD, ArreyTN, HickM, AckermannJ, Acker-PalmerA, KochI, MüllerU, KarasM, VolknandtW (2016) APP is a context-sensitive regulator of the hippocampal presynaptic active zone. PLoS Comput Biol12, e1004832.
125.
SüdhofTC (2012) The presynaptic active zone. Neuron75, 11–25.
FritziusT, BettlerB (2020) The organizing principle of GABA(B) receptor complexes: Physiological and pharmacological implications. Basic Clin Pharmacol Toxicol126 Suppl, 25–34.
128.
MüllerU, KinsS (2002) APP on the move. Trends Mol Med8, 152–155.
129.
StokinGB, LilloC, FalzoneTL, BruschRG, RockensteinE, MountSL, RamanR, DaviesP, MasliahE, WilliamsDS, GoldsteinLSB (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science307, 1282–1288.
